News and Updates

  • Mesothelioma Treatment Center opens study of new treatment

    The Baylor College of Medicine Mesothelioma Treatment Center (MTC) at CHI St. Luke’s Health–Baylor St. Luke’s Medical Center (Baylor St. Luke’s) has begun enrolling patients in a clinical research study for patients with malignant pleural mesothelioma that will investigate the use of two chemotherapy drugs delivered directly to the chest during surgery.

    Read More
  • Mesothelioma Treatment Center at Baylor St. Luke’s Launches Clinical Trial For Cancer Patients

    The Baylor College of Medicine Mesothelioma Treatment Center at Baylor St. Luke’s Medical Center announced today that it has opened a new clinical trial that combines immunotherapy and surgery for the treatment of mesothelioma.

    Read More
  • Study of Potential New Treatment For Mesothelioma Open To Patients

    The Baylor College of Medicine Mesothelioma Treatment Center at Baylor St. Luke’s Medical Center has begun enrolling patients in a clinical research study looking at an investigational drug in patients with malignant pleural mesothelioma who have started on chemotherapy or whose cancer has progressed after initial chemotherapy.

    Read More
  • In Silico Immune Response is the Most Predictive Factor of Overall Survival in Surgically Resected Pleural Mesothelioma

    Malignant pleural mesothelioma (MPM) is an aggressive malignancy that is fatal. Recent evidence has suggested that MPM is an immunogenic tumor that responds favorably to immunotherapy including checkpoint inhibition. We set out to dissect the immune landscape of MPM using mRNA transcriptome data to identify novel immune biomarkers of prognosis and to potentially predict response to immunotherapy.

    Read More
  • Progression of EGFR Mutant Lung Adenocarcinoma

    Despite recent advances in targeted therapy of epidermal growth factor receptor (EGFR)-mutant lung cancer, narrow therapeutic indices and frequent acquired resistance limit their overall success rate. We reasoned that inhibition of immunologic pathways that support tumor growth and maintenance could represent an alternative treatment approach to provide long-lived tumor destruction in this disease.

    Read More
  • New research into the genetic basis of mesothelioma opens new doors for better treatment

    HOUSTON – (Feb. 29, 2016) – Malignant pleural mesothelioma is a deadly malignancy caused by asbestos that affects more than 3,000 individuals in the United States each year. The five-year survival of mesothelioma has increased to about 10 percent at five years with aggressive multimodality therapy, but a report published in Nature Genetics this week provides new hope for more effective treatments.

    Read More
  • New Lung Institute created at Baylor St. Luke's

    Baylor College of Medicine and its clinical partner, St. Luke's Medical Center, on Tuesday announced the creation of a new Lung Institute, a comprehensive center led by an esteemed cancer surgeon they lured from Harvard last year.

    Read More

Let Our Team Answer Your Questions